LONG COVID · POST-ACUTE SEQUELAE OF SARS-COV-2 · NEURO-COVID
A physician-led, laboratory-verified treatment programme targeting the neuroinflammatory, autonomic and cognitive consequences of SARS-CoV-2 infection — tailored to the individual symptom profile, severity and biological markers of each patient.
Request Medical ConsultationAbout the Condition
Post-COVID Neurological Syndrome refers to persistent neurological symptoms that continue for weeks to months after the acute phase of SARS-CoV-2 infection has resolved. Unlike neurodegenerative diseases, this is a post-infectious inflammatory condition — the virus triggers a cascade of neuroinflammation, immune dysregulation and vascular disruption that persists long after viral clearance.
The neurological manifestations are diverse: cognitive impairment ('brain fog'), debilitating fatigue, autonomic dysfunction (heart rate variability, orthostatic intolerance, temperature dysregulation), peripheral neuropathy and sleep disturbance. These symptoms frequently co-occur and can persist for 12 months or longer in a significant proportion of patients.
Current estimates suggest that 10–30% of non-hospitalised COVID-19 patients develop prolonged symptoms, with neurological complaints among the most common and most treatment-resistant. Standard medical management remains largely symptomatic. Our programme targets the underlying biological mechanisms — neuroinflammation, microglial activation, blood-brain barrier disruption and mitochondrial dysfunction — rather than individual symptoms.
Cognitive Post-COVID ('Brain Fog')
Persistent impairment in attention, working memory, executive function and processing speed. Patients report difficulty concentrating, word-finding problems and mental fatigue disproportionate to cognitive effort. MoCA scores typically 2–6 points below pre-illness baseline. Often the most disabling symptom in professionally active patients.
Autonomic Post-COVID (Dysautonomia)
Dysfunction of the autonomic nervous system presenting as postural tachycardia (POTS-like syndrome), orthostatic intolerance, abnormal sweating, gastrointestinal dysmotility and blood pressure instability. Triggered by viral damage to autonomic ganglia and small fibres. Significantly limits daily activity and exercise tolerance.
Peripheral Neuropathic Post-COVID
Small fibre neuropathy, paraesthesias, burning sensations and neuropathic pain affecting the extremities. Confirmed by skin biopsy showing reduced intraepidermal nerve fibre density in a proportion of patients. May present alongside or independently of central neurological symptoms.
Mixed Neurological Post-COVID
Combination of cognitive, autonomic and peripheral symptoms. The most common clinical presentation in our patient population. Reflects the systemic nature of post-COVID neuroinflammation, which affects multiple levels of the nervous system simultaneously.
Our program is individually adapted for all subtypes and all stages of progression.
Important: Each patient is accepted into the programme only after a comprehensive individual medical assessment, which evaluates symptom duration, severity, pre-existing conditions and overall clinical profile.
Post-COVID Neurological Syndrome is not a degenerative disease. It is a post-infectious inflammatory condition, and the prognosis for meaningful recovery is generally more favourable than for progressive neurodegenerative disorders. Our programme is designed to accelerate this recovery by targeting the specific biological mechanisms that sustain persistent symptoms.
Clinical Outcomes
The following data are derived from structured observational analysis of patients treated at BioCells Medical. All figures represent aggregated clinical registry outcomes with longitudinal follow-up. Post-COVID is a relatively recent addition to our treatment programme, and our patient cohort is smaller than for longer-established indications. These are observational results — not randomised controlled trial data — and do not constitute a guarantee of therapeutic effect.
22
Post-COVID neurological patients treated
76%
demonstrated measurable improvement in at least one primary symptom domain within 2–4 months
82%
reported reduction in subjective fatigue severity (FSS decrease ≥1.0 point)
68%
showed cognitive improvement on MoCA (gain of ≥2 points from baseline)
71%
with autonomic symptoms reported clinically meaningful stabilisation of heart rate variability and orthostatic tolerance
64%
maintained sustained improvement at 12-month follow-up
Improved sustained attention and working memory
72%
Reduction in post-exertional fatigue and crash episodes
78%
Improved orthostatic tolerance and exercise capacity
65%
Reduction in peripheral neuropathic symptoms
58%
Restored capacity for professional or daily activity
69%
1–4 weeks
Initial functional response
2–4 months
Clinically meaningful change
6–12 months under continued monitoring
Sustained improvement and stabilisation
Important: Outcomes depend on symptom duration, severity at baseline, pre-existing conditions and individual biological response. Post-COVID patients often respond faster than patients with degenerative conditions, but the degree and timeline of recovery vary significantly between individuals.
Find out if our program can help in your specific case. The initial medical consultation is free and carries no obligation.
Request ConsultationPatient Stories
“I sat down and wrote a full client report without stopping. That had not happened in eight months. My GP kept saying the brain fog would pass on its own. It didn't, not until after treatment. I can think clearly again, and for someone who runs a consultancy, that changes everything.”
Patient
Cognitive Post-COVID · United Kingdom
Every case is assessed individually by our physician team. Request a consultation to discuss your specific situation with our physician team.
Request ConsultationThe BioCells Program
Our Post-COVID neurological programme combines five biological components into a single personalised protocol. The underlying pathology — viral-triggered neuroinflammation, microglial activation, blood-brain barrier disruption, autonomic dysregulation and mitochondrial dysfunction — requires a multi-targeted approach. No two protocols are identical.
No surgery required
Treatment is delivered by intravenous infusion or targeted local injection using specialised medical systems — not surgical instruments.
No general anaesthesia
All procedures are performed under local anaesthesia or without anaesthesia entirely. No respiratory risk.
No risk of immune rejection — autologous option
Where clinically appropriate, we use the patient's own cells. Zero risk of graft-versus-host disease with autologous protocols.
Targets the underlying biology, not individual symptoms
Rather than prescribing separate medications for fatigue, cognition and autonomic symptoms, our protocol targets the shared biological drivers — neuroinflammation, immune dysregulation, mitochondrial dysfunction and blood-brain barrier disruption.
Complements existing medication and rehabilitation
Our programme is compatible with current medications, physiotherapy and cognitive rehabilitation. Patients do not need to discontinue existing treatment before commencing our protocol.
Treatment at your location worldwide
Our medical team is available to conduct treatment at our Warsaw clinic or to travel to the patient's location anywhere in the world.
What It Is
MSCs are multipotent regenerative cells with established immunomodulatory and neuroprotective properties. They are among the most extensively studied cell types in regenerative medicine and have demonstrated safety across thousands of clinical applications worldwide.
How It Is Done
Cells are collected from the patient's own bone marrow (autologous, approximately 50 ml under local anaesthesia) or sourced from a certified donor (allogeneic), depending on individual clinical indications. All cells are expanded, quality-controlled and tested in our certified Warsaw laboratory before administration.
Biological Mechanisms
How This Helps in Post-COVID Neurological Syndrome
In post-COVID neurological syndrome, SARS-CoV-2 triggers a neuroinflammatory cascade that persists long after viral clearance. Activated microglia continue to release inflammatory mediators, damaging neurons and sustaining symptoms. MSCs directly suppress this chronic inflammatory state, reduce microglial overactivation and support the biological conditions needed for neural tissue recovery.
Your Medical Board
The exact combination, dosage, sequencing and delivery method of all five components is determined individually by our medical board for each patient. No two treatment protocols are identical. Your programme is constructed based on your specific symptom profile, duration, biological markers and clinical priorities.
Your protocol is designed individually. Speak with our medical team to understand what your personalised program would include.
Request ConsultationPatient Journey
Your case is reviewed remotely by our physician team. We assess your symptom history, duration since acute infection, current functional status and treatment goals. This consultation is free and carries no obligation.
A detailed review of all medical documentation — including prior cognitive testing, autonomic function studies, inflammatory markers and imaging where available. Our medical board evaluates eligibility, confirms safety parameters and designs your personalised therapeutic protocol.
Your cells are collected, isolated, expanded and quality-tested in our certified Warsaw laboratory. Each batch receives a full traceability certificate. This stage typically takes 2–3 weeks.
Cells are delivered by intravenous infusion or targeted local administration — no surgery, no general anaesthesia. Treatment is available at our Warsaw clinic or with our medical team at your location worldwide. Airport transfers, accommodation and visa support are included in the programme. Where clinically appropriate, our medical board may approve a travelling treatment programme — our medical team flies directly to the patient.
Structured rehabilitation sessions with our specialist, adapted to your specific symptom profile — cognitive training, graded autonomic reconditioning or peripheral neuropathy management. Available at our clinic or remotely coordinated with your local medical team.
Your dedicated coordinator monitors cognitive scores, fatigue levels, autonomic markers and overall well-being. A medical-grade wearable bracelet supports continuous physiological data collection regardless of your location.
The first step is free. Request a medical consultation and our medical consultant will contact you within 24 hours.
Request ConsultationSafety Profile
Cellular therapy is considered safe when delivered under proper medical supervision and according to validated protocols. In our practice, the procedure is well-tolerated by post-COVID patients.
Temporary mild reactions — such as transient local discomfort at the infusion site, slight fatigue or low-grade temperature — may occur in a minority of patients. These are typically short-lived and indicate active immune engagement.
A final medical assessment is performed on-site before every treatment session. If a patient's status has changed — including active reinfection or acute inflammatory flare — the programme may be temporarily modified or postponed for safety reasons.
All contraindications are evaluated individually. A contraindication in one clinical context does not necessarily preclude treatment in a different context — this is always determined by physician assessment.
Standard Contraindications
Active acute infection or fever
Active malignancy or ongoing chemotherapy / radiotherapy
Severe decompensated cardiac or renal failure
Pregnancy
Post-Treatment
Dedicated rehabilitation specialist
monitors cognitive recovery, autonomic stability and fatigue levels
Personalised rehabilitation programme
graded cognitive training, autonomic reconditioning and activity pacing adapted to recovery phase
Medical-grade wearable monitoring
continuous physiological data collection supporting clinical decision-making
Long-term coordinator support
proactive check-ins, clinical guidance and response to any changes in status
Continued clinical access
our medical team remains available for ongoing reassessment and protocol adjustment
The post-treatment period is medically critical. Post-COVID recovery follows a non-linear trajectory — improvements may occur in stages, and temporary symptom fluctuations are expected. Structured follow-up ensures that progress is tracked, rehabilitation is adjusted and any setbacks are addressed promptly by our clinical team.
Get Started
If you are living with persistent neurological symptoms after COVID-19, our medical team is available for a free, no-obligation medical consultation — based on your symptom profile, duration and individual clinical status.
We review every inquiry personally. You will speak with a physician, not an administrator.
Submit your case online or by phone
Our medical consultant contacts you to review your documents
The medical board presents your personalised treatment plan
Request a Consultation
Tell us about your condition. Our medical consultant will contact you within 24 hours to review your documents.
Open Consultation FormMultilingual coordination — English, Italian, French, Russian, Polish
Evidence Base
Our clinical approach is informed by and consistent with published research in the field of regenerative medicine.
